NASH Treatment Pipeline: Why Current Approvals Miss the Mark
New NASH therapies are getting approved, but the mechanisms tell a different story about what actually works for fatty liver disease.
Published May 21, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This review examines the current landscape of approved and investigational treatments for NASH (now called metabolic dysfunction-associated steatohepatitis). The authors analyze mechanisms of action across different therapeutic classes and assess where the field is heading based on clinical trial data.
Why It Matters
NASH affects 3-5% of the global population and represents the liver manifestation of metabolic syndrome. What's striking about current approvals is how they largely miss the core pathophysiology. Most approved therapies target downstream inflammation and fibrosis rather than addressing the fundamental insulin resistance and lipid dysregulation driving the disease.
The pipeline shows promise with FXR agonists, GLP-1 receptor agonists, and combination approaches. FXR activation directly addresses bile acid metabolism and hepatic glucose production—two central mechanisms in NASH progression. GLP-1 agonists like semaglutide are showing impressive results not just for weight loss but for direct hepatoprotective effects, with some trials reporting 50-70% reductions in liver fat content.
What's particularly interesting is the emerging data on thyroid hormone receptor-β agonists. These compounds can dramatically increase hepatic fatty acid oxidation while avoiding systemic thyrotoxic effects. Early trials show 30-40% reductions in liver fat within 12-16 weeks.
What I'd Watch For
The major limitation across NASH trials is the reliance on surrogate endpoints—liver enzymes, imaging, even biopsy scores—rather than hard clinical outcomes. We're approving drugs based on histological improvements without knowing if they prevent cirrhosis, hepatocellular carcinoma, or death. The 10-20 year follow-up data simply doesn't exist yet.
Also concerning is how few trials adequately control for concurrent metabolic interventions. When patients lose 10-15% body weight during a drug trial, how much of the liver improvement is the drug versus the weight loss?
Bottom Line
Current NASH approvals are largely symptomatic treatments for a metabolic disease. The next generation targeting core metabolic pathways looks more promising, but we're still years away from knowing which approaches actually change long-term outcomes. For now, aggressive metabolic optimization remains the foundation of any NASH protocol.